Media Center Overview Blog Posts Media Highlights News Releases Presentations & Publications Get the latest updates from our team on new research, thought leadership, and company news and events. Blog Posts See All Aug 07, 2026 Blog Posts Designing Beyond Tolerability Limits: Advancing GB-4362 Into Clinical Development Read More Jul 14, 2026 Blog Posts Designing Beyond Viral Evolution: Peer-Reviewed First-in-Human Results for GB-0669 Read More Media Highlights See All Aug 05, 2026 Media Highlights Generative Biology Is Rewriting The Rules Of Drug Discovery View on: Forbes Jun 30, 2026 Media Highlights Q&A: Generate Biomedicines CTO talks AI advancements View on: TechTarget News Releases See All Aug 06, 2026 News Releases Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update Read More May 28, 2026 News Releases Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference Read More Presentations & Publications See All Jul 14, 2026 Presentations & Publications Randomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV‑2 Spike S2 Stem Helix Read More
Aug 07, 2026 Blog Posts Designing Beyond Tolerability Limits: Advancing GB-4362 Into Clinical Development Read More
Jul 14, 2026 Blog Posts Designing Beyond Viral Evolution: Peer-Reviewed First-in-Human Results for GB-0669 Read More
Aug 05, 2026 Media Highlights Generative Biology Is Rewriting The Rules Of Drug Discovery View on: Forbes
Jun 30, 2026 Media Highlights Q&A: Generate Biomedicines CTO talks AI advancements View on: TechTarget
Aug 06, 2026 News Releases Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update Read More
May 28, 2026 News Releases Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference Read More
Jul 14, 2026 Presentations & Publications Randomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV‑2 Spike S2 Stem Helix Read More
